单位:[1]State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[3]Department of Internal Medicine, Beijing Friendship Hospital, Medical Health Center, Capital Medical University, Beijing, China临床科室医保中心首都医科大学附属北京友谊医院[4]Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, USA[5]Department Of Cardiovascular Surgery, Xiangya Hospital, Central South University, Changsha, China[6]Department of Cardiology, Shanghai East Hospital, Tongji University, Shanghai, China
Background Robust data regarding genotype-phenotype correlations in left ventricular noncompaction cardiomyopathy (LVNC) are lacking. Methods About 72 cardiomyopathy-related genes were comprehensively screened in a cohort of LVNC patients using targeted sequencing. Baseline and follow-up data were collected. The primary endpoint was a composite of death and heart transplantation. Results A total of 83 unrelated adult patients were included in analyses. Following stringent classification according to the American College of Medical Genetics and Genomics (ACMG) guidelines, 36 pathogenic variants of 14 genes were detected in 32 patients. Among them, 12 patients carried at least one nonsarcomere variant (NSV). At baseline, NSV carriers had a higher frequency of atrial fibrillation, but lower left ventricular ejection fraction, than did noncarriers. During a median follow-up of 4.2 years, NSV carriers experienced a higher rate of the primary endpoint compared with noncarriers. There was no significant difference in the rate between carriers of sarcomere variant (SV) and noncarriers, as well as between carriers of SV and NSV. The presence of NSV was associated with an increased risk of the primary endpoint independent of age, sex, and cardiac function (hazard ratio: 3.61, 95% confidence interval: 1.42-9.19, p = .002). Conclusion NSV may act as a genetic modifier and worsen the clinical phenotype in patients with LVNC.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81470460]
第一作者单位:[1]State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[3]Department of Internal Medicine, Beijing Friendship Hospital, Medical Health Center, Capital Medical University, Beijing, China
通讯作者:
通讯机构:[2]Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[6]Department of Cardiology, Shanghai East Hospital, Tongji University, Shanghai, China[*1]Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167, Beilishilu, Xicheng District, Beijing 100037, China.
推荐引用方式(GB/T 7714):
Shijie Li,Ce Zhang,Nana Liu,et al.Clinical implications of sarcomere and nonsarcomere gene variants in patients with left ventricular noncompaction cardiomyopathy[J].MOLECULAR GENETICS & GENOMIC MEDICINE.2019,7(9):doi:10.1002/mgg3.874.
APA:
Shijie Li,Ce Zhang,Nana Liu,Hui Bai,Cuihong Hou&Jielin Pu.(2019).Clinical implications of sarcomere and nonsarcomere gene variants in patients with left ventricular noncompaction cardiomyopathy.MOLECULAR GENETICS & GENOMIC MEDICINE,7,(9)
MLA:
Shijie Li,et al."Clinical implications of sarcomere and nonsarcomere gene variants in patients with left ventricular noncompaction cardiomyopathy".MOLECULAR GENETICS & GENOMIC MEDICINE 7..9(2019)